Panayiotidis, P. Et Al. 2021. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Advances , vol.5, no.3 , 823-828.

Panayiotidis, P., Follows, G. A., Mollica, L., Nagler, A., ÖZCAN, M., Santoro, A., ... Stevens, D.(2021). Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Advances , vol.5, no.3, 823-828.

Panayiotidis, Panayiotis Et Al. "Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma," Blood Advances , vol.5, no.3, 823-828, 2021

Panayiotidis, Panayiotis Et Al. "Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma." Blood Advances , vol.5, no.3, pp.823-828, 2021

Panayiotidis, P. Et Al. (2021) . "Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma." Blood Advances , vol.5, no.3, pp.823-828.

@article{article, author={Panayiotis Panayiotidis Et Al. }, title={Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma}, journal={Blood Advances}, year=2021, pages={823-828} }